197 related articles for article (PubMed ID: 22260266)
1. Safety of older generations of gadolinium in mild-to-moderate renal failure.
Khatami SM; Mahmoodian M; Zare E; Pashang M
Ren Fail; 2012; 34(2):176-80. PubMed ID: 22260266
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
Kay J
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
5. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
6. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
8. The use of gadolinium for arterial interventions.
Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC
Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
Penfield JG; Reilly RF
Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
[TBL] [Abstract][Full Text] [Related]
10. [Nephrogenic systemic fibrosis and use of MR contrast media].
Christiansen RE; Sviland L; Sekse I; Svarstad E
Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
[TBL] [Abstract][Full Text] [Related]
11. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.
Pietsch H; Raschke M; Ellinger-Ziegelbauer H; Jost G; Walter J; Frenzel T; Lenhard D; Hütter J; Sieber MA
Invest Radiol; 2011 Jan; 46(1):48-56. PubMed ID: 20938346
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
14. Large sample of nephrogenic systemic fibrosis cases from a single institution.
Lee CU; Wood CM; Hesley GK; Leung N; Bridges MD; Lund JT; Lee PU; Pittelkow MR
Arch Dermatol; 2009 Oct; 145(10):1095-102. PubMed ID: 19841395
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis.
Richmond H; Zwerner J; Kim Y; Fiorentino D
Arch Dermatol; 2007 Aug; 143(8):1025-30. PubMed ID: 17709661
[TBL] [Abstract][Full Text] [Related]
16. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report.
Wiedemeyer K; Kutzner H; Abraham JL; Thakral C; Carlson JA; Tran TA; Hausser I; Hartschuh W
Am J Dermatopathol; 2009 Oct; 31(7):674-81. PubMed ID: 19633532
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine.
Hope TA; Herfkens RJ; Denianke KS; LeBoit PE; Hung YY; Weil E
Invest Radiol; 2009 Mar; 44(3):135-9. PubMed ID: 19151610
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
